Characteristics and control of severe hypertension in a specialist, private practice in Jamaica

West Indian Medical Journal

Volumn 54, Issue 5, 2005, Pages 315-318

  Lalljie, G R ^a   Lalljie, S E ^b  

^a Baywest Centre   (Jamaica)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSULTATION; DATA ANALYSIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DYSLIPIDEMIA; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; JAMAICA; LONG TERM CARE; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; OBESITY; PRESCRIPTION; PRIVATE PRACTICE; RETROSPECTIVE STUDY; SYMPTOM;

EID: 30644477956     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0043-31442005000500008     Document Type: Article

References (17)

1. 9 World Health Organization-International Society of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-3.
2. Chobanian AV, Bakris GL, Black HR, Cushnain WC, Green LA, Izzo JL Jr. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the report. JNC7. JAMA 2003; 289: 3560-72.
3. European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
4. Hansson L, Zanchetti A, Carranthers SG, Dahlef B, Elmfeott D, Julius S et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
5. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid lowering treatment to prevent heart attack (ALLHAT) trial. JAMA 2002; 288: 23:2981-2997.
6. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-20.
7. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.
8. VALUE Collaborative Group. Valsartan antihypertensive long-term use evaluation trial. Lancet 2004; 363.
9. Wilks R, Sargeant LA, Gulliford M, Reid M, Forrester T. Quality of care of hypertension in three clinical settings in Jamaica. West Indian Med J 2000; 49: 220-5.
10. Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles, Campos C et al. Blood pressure control and physician management in hospital hypertension units in Spain. Hypertension 2004; 43: 1338-44.
11. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoigne J, Charleston J et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized control trial. JAMA 2001; 285: 2719-28.
12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl Med J 1998; 338: 645-52.
13. Amar J, Chamontin B, Genes N, Cabtet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003; 21: 1199-205.
14. Yusuf S, Pagenais G, Pogue J, Bosh J, Sleight P. Vitamin E supplementation and cardiovascular events in high risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 2000; 342: 154-60.
15. Fox Km; The European Trial on reduction of cardiac events with Perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multi-centre trial (the EUROPA study). Lancet 2003; 362: 782-8.
16. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure lowering regimen among 6,105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-41.
17. Kjellgren KI, Ahlner J, Dahlof B, Gill H, Hedner T, Saljo R. Perceived symptoms amongst hypertensive patients in routine clinical practice - a population-based study. J Intern Med 1998; 244: 325-32.